Lapatinib Terminated Phase 2 Trials for Malignant Melanoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01264081Lapatinib in Stage IV Melanoma With ERBB4 Mutations